3 Health Care Stocks Nudging The Sector Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 55 points (0.3%) at 16,661 as of Tuesday, May 27, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,943 issues advancing vs. 1,024 declining with 173 unchanged.

The Health Care sector currently sits up 1.4% versus the S&P 500, which is up 0.5%. Top gainers within the sector include Isis Pharmaceuticals ( ISIS), up 7.7%, Alnylam Pharmaceuticals ( ALNY), up 6.0%, Incyte ( INCY), up 3.1%, Vertex Pharmaceuticals ( VRTX), up 2.6% and Biogen Idec ( BIIB), up 1.9%. On the negative front, top decliners within the sector include Edwards Lifesciences ( EW), down 2.2%, AstraZeneca ( AZN), down 1.0%, Baxter International ( BAX), down 0.7% and Thermo Fisher Scientific ( TMO), down 0.5%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Health Care sector higher today. As of noon trading, Regeneron Pharmaceuticals is up $6.99 (2.4%) to $304.76 on light volume. Thus far, 330,620 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $298.65-$307.09 after having opened the day at $299.54 as compared to the previous trading day's close of $297.77.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $29.4 billion and is part of the drugs industry. Shares are up 8.2% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and weak operating cash flow. Get the full Regeneron Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $0.25 (0.5%) to $49.04 on light volume. Thus far, 2.5 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8.5 million shares. The stock has ranged in price between $48.67-$49.07 after having opened the day at $48.89 as compared to the previous trading day's close of $48.79.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $80.9 billion and is part of the drugs industry. Shares are down 8.2% year-to-date as of the close of trading on Friday. Currently there are 10 analysts who rate Bristol-Myers Squibb Company a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Bristol-Myers Squibb Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Celgene ( CELG) is up $2.76 (1.8%) to $152.89 on average volume. Thus far, 1.6 million shares of Celgene exchanged hands as compared to its average daily volume of 3.6 million shares. The stock has ranged in price between $150.01-$153.24 after having opened the day at $151.00 as compared to the previous trading day's close of $150.13.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene has a market cap of $60.1 billion and is part of the drugs industry. Shares are down 11.2% year-to-date as of the close of trading on Friday. Currently there are 21 analysts who rate Celgene a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices